These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Addressing the challenge of extended-spectrum beta-lactamases. Zahar JR; Lortholary O; Martin C; Potel G; Plesiat P; Nordmann P Curr Opin Investig Drugs; 2009 Feb; 10(2):172-80. PubMed ID: 19197795 [TBL] [Abstract][Full Text] [Related]
25. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis. Wagenlehner FM; Weidner W; Naber KG Clin Pharmacokinet; 2007; 46(4):291-305. PubMed ID: 17375981 [TBL] [Abstract][Full Text] [Related]
27. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Lu PL; Liu YC; Toh HS; Lee YL; Liu YM; Ho CM; Huang CC; Liu CE; Ko WC; Wang JH; Tang HJ; Yu KW; Chen YS; Chuang YC; Xu Y; Ni Y; Chen YH; Hsueh PR Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S37-43. PubMed ID: 22749057 [TBL] [Abstract][Full Text] [Related]
28. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Paul M; Silbiger I; Grozinsky S; Soares-Weiser K; Leibovici L Cochrane Database Syst Rev; 2006 Jan; (1):CD003344. PubMed ID: 16437452 [TBL] [Abstract][Full Text] [Related]
29. Predictive value of prior colonization and antibiotic use for third-generation cephalosporin-resistant enterobacteriaceae bacteremia in patients with sepsis. Rottier WC; Bamberg YR; Dorigo-Zetsma JW; van der Linden PD; Ammerlaan HS; Bonten MJ Clin Infect Dis; 2015 Jun; 60(11):1622-30. PubMed ID: 25694654 [TBL] [Abstract][Full Text] [Related]
33. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. Toner L; Papa N; Aliyu SH; Dev H; Lawrentschuk N; Al-Hayek S World J Urol; 2016 Jul; 34(7):1031-7. PubMed ID: 26511749 [TBL] [Abstract][Full Text] [Related]
34. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis. Sfeir MM; Askin G; Christos P Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138 [TBL] [Abstract][Full Text] [Related]
35. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Bush K Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989 [TBL] [Abstract][Full Text] [Related]
36. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE; Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681 [TBL] [Abstract][Full Text] [Related]